Sai Parenterals Subsidiary Renews Australian OTC Deal for AUD 202M
Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its exclusive Over-The-Counter (OTC) medicines supply agreement with leading Australian pharmacy networks. The landmark 7½-year deal is valued at AUD 202 million (approximately INR 1300 crores), with an option for a further 3-year extension. The agreement includes adding 12 new products annually, enhancing the contract's value and scope. This renewal strengthens Noumed's position as a strategic supply partner and expands Sai Parenterals' international footprint, ensuring predictable, recurring revenues and enhancing manufacturing scale. The deal underscores confidence in Noumed's regulatory, quality, and supply chain capabilities in a highly regulated market.
Key Highlights
- Subsidiary Noumed Pharmaceuticals renews exclusive OTC supply agreement in Australia.
- Deal valued at AUD 202 Million (INR 1300 Crores) over 7½ years.
- Agreement includes adding 12 new products annually, increasing contract value.
- Secures predictable, recurring revenues and strengthens international business.
- Demonstrates trust in Noumed's regulatory and supply chain capabilities.
Price Impact
More from SAIPARENT